Gagandeep Singh, MD
Hospitalist · Hartford, CTNPI 1003055021
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Johnson & Johnson at 40.9% of the total. Reporting peaked in 2022 at $760 and has fallen 55.8% since, to $336 in 2025. Among hospitalist clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $27.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Pfizer$717
- AstraZeneca$512
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$163
- CSL Behring$157
- Novartis$150
- plus $496 from 12 others
What the payments were for
- Food & beverage$3,711100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 33 | $1,518 |
| Pfizer | 32 | $717 |
| AstraZeneca(2 entities) | 27 | $512 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $163 |
| CSL Behring | 6 | $157 |
| Novartis | 8 | $150 |
| Boehringer Ingelheim | 3 | $79 |
| Ferring Pharmaceuticals Inc. | 3 | $73 |
| Alcresta Therapeutics, Inc. | 2 | $66 |
| Astellas Pharma US Inc | 2 | $55 |
| Sanofi | 2 | $44 |
| Alnylam Pharmaceuticals Inc. | 1 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Mayne Pharma Commercial LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$532
How this compares
$3,711 in reported general payments places this provider in the 95th percentile of 349 hospitalist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 979 | $301,929 |
| IngrezzaValbenazine Tosylate | 35 | $113,167 |
| AustedoDeutetrabenazine | 39 | $89,252 |
| Dupixent SyringeDupilumab | 18 | $68,352 |
| Breo ElliptaFluticasone/Vilanterol | 152 | $66,026 |
| TradjentaLinagliptin | 224 | $54,389 |
| JanuviaSitagliptin Phosphate | 188 | $53,723 |
| XareltoRivaroxaban | 171 | $48,832 |
| JardianceEmpagliflozin | 128 | $39,576 |
| MounjaroTirzepatide | 36 | $35,715 |
| XifaxanRifaximin | 22 | $31,601 |
| Risperdal ConstaRisperidone Microspheres | 24 | $30,089 |
| LinzessLinaclotide | 45 | $25,856 |
| Atorvastatin Calcium | 1,481 | $23,656 |
| MyrbetriqMirabegron | 97 | $22,785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $717 | $301,929979 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $21 | $113,16735 claims |
| Boehringer IngelheimTradjenta, Jardiance, Combivent Respimat | $79 | $104,386372 claims |
| Johnson & JohnsonXarelto, Risperdal Consta, Invega Sustenna | $1,518 | $100,944207 claims |
| AstraZenecaLokelma, Farxiga | $512 | $32,10660 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $163 | $31,60122 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $22,78597 claims |
| NovartisEntresto | $150 | $14,38840 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 349 hospitalist providers in Connecticut.
Other hospitalist in Hartford
- Roy KellermanHartford$5K
- Muhammad FarooqHartford$5K
- Joseph FuscoHartford$4K
- Edgar NautHartford$4K
- Gagan SinghHartford$4K
- Vanessa PauigHartford$3K
- Syed AliHartford$2K
- Anuradha KapurHartford$2K
- John OsowskiHartford$2K
- Praveen JosephHartford$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.